Pablo Sardi, PhD, is an R&D director in the Neurobiology Unit at Sanofi. Dr. Sardi holds a PharmD and a PhD in pharmacology from the University of Buenos Aires in Argentina. Dr. Sardi's post-doctoral research at Harvard Medical School/Children's Hospital Boston focused on signaling pathways relevant to neurodegenerative diseases. In 2007, Dr. Sardi moved to Genzyme to purse his longstanding interest in discovering and delivering therapies for those with high unmet medical needs. Dr. Sardi currently leads a team investigating various therapeutic approaches for Parkinson's disease. These efforts span from the validation of targets and pre-clinical research to the discovery of translational biomarkers and initial clinical development. His team has made several original discoveries, including the description of the first pre-clinical model of Gaucher-related synucleinopathy and the demonstration that modulation of the glucocerebrosidase pathway might constitute a potential therapeutic approach for Parkinson's.